Production (Stage)
Amneal Pharmaceuticals, Inc.
AMRX
$7.16
-$0.03-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.42% | 16.73% | 12.32% | 12.37% | 9.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.42% | 16.73% | 12.32% | 12.37% | 9.82% |
| Cost of Revenue | 13.64% | 16.26% | 11.30% | 10.90% | 7.83% |
| Gross Profit | 13.05% | 17.55% | 14.14% | 15.07% | 13.43% |
| SG&A Expenses | 9.53% | 10.88% | 8.02% | 10.04% | 9.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,853.76% | 108.79% | 103.84% | 104.33% | 103.59% |
| Total Operating Expenses | 12.77% | 15.24% | 11.01% | 9.78% | 6.85% |
| Operating Income | 18.03% | 28.33% | 22.30% | 34.26% | 36.68% |
| Income Before Tax | 154.52% | -36.61% | -446.56% | -883.39% | 57.05% |
| Income Tax Expenses | 83.46% | 123.18% | 822.52% | 414.37% | 29.18% |
| Earnings from Continuing Operations | 126.95% | -51.63% | -477.87% | -1,274.52% | 53.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.03% | -21.94% | -33.53% | -209.31% | -139.13% |
| Net Income | 92.27% | -39.16% | -1,886.83% | -8,426.17% | -25.17% |
| EBIT | 18.03% | 28.33% | 22.30% | 34.26% | 36.68% |
| EBITDA | 13.01% | 16.71% | 10.84% | 14.76% | 14.81% |
| EPS Basic | 92.50% | -22.41% | -1,134.95% | -4,181.38% | 36.92% |
| Normalized Basic EPS | -582.98% | -291.60% | -92.42% | -87.64% | -99.13% |
| EPS Diluted | 92.56% | -20.20% | -1,311.84% | -2,572.65% | 37.04% |
| Normalized Diluted EPS | -592.63% | -291.10% | -92.43% | -87.65% | -99.12% |
| Average Basic Shares Outstanding | 44.32% | 75.61% | 91.28% | 66.63% | 41.75% |
| Average Diluted Shares Outstanding | 45.85% | 75.36% | 90.82% | 68.83% | 42.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |